Key Findings
The antidepressants drugs, devices and therapies market in Europe is undergoing an intensified growth of 1.77% CAGR during the forecasting years of 2019-2027. The rising population of depression has given an opportunity for the market in Europe to innovate the drug and therapies with the reduced side effects and greater efficacy along with accelerating the prevalence of depression disorder.

Market Insights
Germany, the United Kingdom, France, Spain, Italy, Russia and the remaining countries forming the Rest of Europe are considered for this market study. For treat depression cases which are growing globally, the demand for antidepressant drugs are also increasing and thus, improving the sales of antidepressant drugs worldwide. Moreover, research and development activities in the global drugs market is expected to discover new, cost-effective and impactful antidepressants in the future, thereby making the bargaining power of buyers as moderate.

Competitive Insights
The companies operating in the region are Eli Lilly and Company, Abbot Laboratories, Allergan PLC, Pfizer, Neuronetics, Mayo Clinic, H. Lundbeck AS, Brainsway, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd. and GlaxoSmithKline.